FindTrial
Sign In

GPRC5D-TARGETED CAR T

DRUG2 trials

Sponsors

Celgene Corp.

Conditions

Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma

Phase 2

LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS
RecruitingCTIS2023-504201-36-00
Celgene Corp.Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.
Start: 2018-12-21Target: 214Updated: 2025-10-27

Phase 3

A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
RecruitingCTIS2024-515279-37-00
Celgene Corp.Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
Start: 2025-04-17Target: 189Updated: 2025-11-11